Related Experiment Video

Updated: Mar 17, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

851

Formononetin exhibits anti-hyperglycemic activity in alloxan-induced type 1 diabetic mice

Guizhen Qiu1, Wei Tian2, Mei Huan2

  • 11 Department of Health, Linyi People's Hospital of Shandong University, Linyi 276003, Shandong Province, China.

Experimental Biology and Medicine (Maywood, N.J.)
|July 15, 2016
PubMed

Insights

Formononetin demonstrates anti-hyperglycemic effects in diabetic mice by improving insulin secretion and regeneration while reducing apoptosis. This natural compound aids in managing blood glucose levels and promoting overall metabolic health.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Endocrinology

Background:

  • Type 1 diabetes is characterized by hyperglycemia and pancreatic islet dysfunction.
  • Alloxan-induced diabetes in mice serves as a model for studying anti-diabetic agents.
  • Formononetin is a natural compound with potential therapeutic properties.

Purpose of the Study:

  • To investigate the anti-hyperglycemic activity of formononetin in alloxan-induced type 1 diabetic mice.
  • To elucidate the underlying mechanisms of formononetin's action on diabetes-related indices.
  • To assess the effects of formononetin on pancreatic islet cell apoptosis and regeneration.

Main Methods:

  • Alloxan was used to induce type 1 diabetes in mice.
  • Formononetin was administered orally at doses of 5, 10, and 20 mg/kg.
  • Measurements included body weight, fasting blood glucose, hepatic glycogen, serum insulin, and glucagon.
  • Pancreatic and liver tissues were analyzed for mRNA and protein levels of key diabetes-related genes (e.g., Fas, Caspase-3, PDX-1, IRS-2, GK, GLUT2, G6Pase) using qPCR and Western blot.
  • Oral glucose tolerance tests were performed.

Main Results:

  • Formononetin treatment reversed hyperglycemia, reduced fasting blood glucose, and improved oral glucose tolerance.
  • Formononetin increased body weight gain, hepatic glycogen levels, and serum insulin.
  • Formononetin inhibited apoptosis by decreasing Fas and Caspase-3 expression and promoted islet B cell regeneration by increasing PDX-1, IRS-2, GK, and GLUT2 expression in the pancreas.
  • Formononetin enhanced hepatic glycolysis by increasing glucokinase expression and decreasing glucose-6-phosphatase expression in the liver.

Conclusions:

  • Formononetin exhibits significant anti-hyperglycemic activity in a mouse model of type 1 diabetes.
  • The mechanism involves inhibiting islet B cell apoptosis and promoting islet B cell regeneration and insulin secretion.
  • Formononetin also improves glucose metabolism through enhanced hepatic glycogen synthesis and glycolysis.
Keywords:
Formononetinanti-hyperglycemic activityglycolysisinsulin secretionislet B cell apoptosis and regenerationtype 1 diabetes

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.4K
Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes11:03

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

4.5K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
808
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
879
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.5K